Bioengineering: α1-Proteinase inhibitor site-specific mutagenesis. The prospect for improving the inhibitor

Maurizio Luisetti, James Travis

Research output: Contribution to journalArticle

Abstract

α1-Proteinase inhibitor (α1-PI) augmentation therapy has been licensed for treatment of α1-PI-deficient individuals with pulmonary emphysema. The currently available product is purified from pooled human plasma. To obtain larger amounts of protein free from possible unknown plasma contaminants, human α1-PI has been produced by recombinant DNA. Since wild- type α1-PI is susceptible to oxidative impairment, several α1-PI variants in which the active site oxidation-sensitive residue is replaced by inert residues have been constructed. This article is aimed at reviewing the history biological efficacy, advantages, disadvantages, and concerns linked to α1-PI recombinant DNA and site-specific mutagenesis technology.

Original languageEnglish
JournalChest
Volume110
Issue number6 SUPPL.
Publication statusPublished - 1996

Keywords

  • α-PI deficiency
  • neutrophil elastase
  • oxidants
  • pulmonary emphysema
  • recombinant DNA

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Fingerprint Dive into the research topics of 'Bioengineering: α1-Proteinase inhibitor site-specific mutagenesis. The prospect for improving the inhibitor'. Together they form a unique fingerprint.

  • Cite this